AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$ACOG

Opaleye Management Inc. purchased $266K of ACOG (indirect holdings)

Opaleye Management Inc. purchased 32,090 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $8.28 ($8.23–$8.33, $0.27M total) across 2 trades over 2026-10-22 to 2026-10-23.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Oct 26, 2026, 8:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ACOG
Neutral
medium confidence
Mentioned
$ACOG
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGNeutralLow
01

Why it matters

The modest purchase may provide short‑term support but is unlikely to move the stock significantly.

02

Market read

Primary insider filing with limited trading relevance due to small transaction size.

03

What to watch

Potential upcoming dilution or secondary offerings could offset the buying signal.

Relevance 5/10Novelty 4/10Timing: after-hours filing on 2026-10-26

Background

SEC Form 4 filing discloses an insider transaction by Opaleye Management, a 10% owner of Alpha Cognition Inc.

Company-level read

Ticker impact

$ACOGNeutralMedium confidence
Context

Opaleye Management Inc. purchased 32,090 shares of Alpha Cognition Inc. for $265,820, increasing its stake to 3,291,984 shares.

Expected impact

likely slight upward pressure as the market prices the 10% owner’s additional stake.

Evidence & confidence

The transaction size is small relative to market cap, but the buyer is a 10% owner, which can be viewed as a vote of confidence.

Market effects

Sector

Minimal impact on the broader AI/tech sector.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The purchase may be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • company
    Alpha Cognition Inc.

    Issuer of the shares purchased.

  • entity
    Opaleye Management Inc.

    Insider and 10% owner executing the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACOG insider trading history →

Related articles

$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

yahoo.com
$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

investing.com
$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.

thestarphoenix.com